The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions
The global tuberculosis burden remains substantial, with more than 10 million people newly
ill per year. Nevertheless, tuberculosis incidence has slowly declined over the past decade …
ill per year. Nevertheless, tuberculosis incidence has slowly declined over the past decade …
The COVID-19 and TB syndemic: the way forward
A Trajman, I Felker, LC Alves, I Coutinho… - … of Tuberculosis and …, 2022 - ingentaconnect.com
Together, SARS-CoV-2 and M. tuberculosis have killed approximately 5.7 million people
worldwide over the past 2 years. The COVID-19 pandemic, and the non-pharmaceutical …
worldwide over the past 2 years. The COVID-19 pandemic, and the non-pharmaceutical …
Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study
Summary Background The SARS-CoV-2 omicron variant of concern was identified in South
Africa in November, 2021, and was associated with an increase in COVID-19 cases. We …
Africa in November, 2021, and was associated with an increase in COVID-19 cases. We …
Clinical severity of SARS-CoV-2 Omicron BA. 4 and BA. 5 lineages compared to BA. 1 and Delta in South Africa
Omicron lineages BA. 4 and BA. 5 drove a fifth wave of COVID-19 cases in South Africa.
Here, we use the presence/absence of the S-gene target as a proxy for SARS-CoV-2 …
Here, we use the presence/absence of the S-gene target as a proxy for SARS-CoV-2 …
[HTML][HTML] SARS-CoV-2 seroprevalence in a rural and urban household cohort during first and second waves of infections, South Africa, July 2020–March 2021
J Kleynhans, S Tempia, N Wolter… - Emerging infectious …, 2021 - ncbi.nlm.nih.gov
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections may be
underestimated because of limited access to testing. We measured SARS-CoV-2 …
underestimated because of limited access to testing. We measured SARS-CoV-2 …
Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical …
Background WHO has established a Global Clinical Platform for the clinical characterisation
of COVID-19 among hospitalised individuals. We assessed whether people living with HIV …
of COVID-19 among hospitalised individuals. We assessed whether people living with HIV …
Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19
Background We describe demographic features, treatments and clinical outcomes in the
International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID …
International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID …
Effects of tuberculosis and/or HIV-1 infection on COVID-19 presentation and immune response in Africa
E Du Bruyn, C Stek, R Daroowala… - Nature …, 2023 - nature.com
Few studies from Africa have described the clinical impact of co-infections on SARS-CoV-2
infection. Here, we investigate the presentation and outcome of SARS-CoV-2 infection in an …
infection. Here, we investigate the presentation and outcome of SARS-CoV-2 infection in an …
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised …
Background There is a paucity of data on COVID-19 vaccines in people living with HIV-1,
who could be at increased risk of severe illness and death from COVID-19. We evaluated …
who could be at increased risk of severe illness and death from COVID-19. We evaluated …
Africa: tackle HIV and COVID-19 together
Africa: tackle HIV and COVID-19 together Skip to main content Thank you for visiting nature.com.
You are using a browser version with limited support for CSS. To obtain the best experience …
You are using a browser version with limited support for CSS. To obtain the best experience …